Newest Rating: Will finnCap Under Review Rating Harm Dechra Pharmaceuticals PLC (LON:DPH) Stock Price Today?

November 29, 2016 - By Darrin Black

Dechra Pharmaceuticals PLC (LON:DPH) Surprise By finnCap

In a research note sent to investors and clients on 29 November, finnCap reissued their under review rating on Dechra Pharmaceuticals PLC (LON:DPH) shares.

Dechra Pharmaceuticals plc (LON:DPH) Ratings Coverage

Out of 10 analysts covering Dechra Pharmaceuticals PLC (LON:DPH), 7 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 70% are positive. GBX 1520 is the highest target while GBX 129 is the lowest. The GBX 1311.89 average target is 2.97% above today’s (GBX 1274) stock price. Dechra Pharmaceuticals PLC has been the topic of 59 analyst reports since August 3, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by Stifel Nicolaus given on Tuesday, March 15. Jefferies maintained Dechra Pharmaceuticals plc (LON:DPH) on Wednesday, September 7 with “Hold” rating. The company was maintained on Tuesday, July 12 by Numis Securities. The stock of Dechra Pharmaceuticals plc (LON:DPH) has “Buy” rating given on Friday, October 21 by N+1 Singer. Numis Securities maintained the stock with “Add” rating in Thursday, October 27 report. As per Thursday, January 14, the company rating was maintained by Jefferies. The stock has “Buy” rating given by Investec on Thursday, March 17. Panmure Gordon maintained the shares of DPH in a report on Friday, October 23 with “Buy” rating. Jefferies maintained Dechra Pharmaceuticals plc (LON:DPH) on Tuesday, July 26 with “Hold” rating. On Friday, June 3 the stock rating was downgraded by Jefferies to “Hold”.

About 52,448 shares traded hands. Dechra Pharmaceuticals plc (LON:DPH) has risen 16.82% since April 29, 2016 and is uptrending. It has outperformed by 11.56% the S&P500.

Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The company has a market cap of 1.18 billion GBP. The Firm is engaged in development, manufacture and marketing of products for veterinarians. It has a 89.54 P/E ratio. The Company’s divisions include European Pharmaceuticals, North American Pharmaceuticals and Pharmaceuticals Research and Development.

More notable recent Dechra Pharmaceuticals plc (LON:DPH) news were published by: Prnewswire.com which released: “Dechra Pharmaceuticals PLC, Agrees Acquisition of US-based Putney, Inc for …” on March 15, 2016, also Prnewswire.com with their article: “Dechra Pharmaceuticals PLC: Half-Yearly Financial Report 2016” published on February 22, 2016, Fool.Co.Uk published: “Is Dechra Pharmaceuticals plc a better buy than GlaxoSmithKline plc after …” on September 05, 2016. More interesting news about Dechra Pharmaceuticals plc (LON:DPH) were released by: Prnewswire.com and their article: “Dechra® Pharmaceuticals PLC (Dechra or the Group) : Trading Update” published on January 14, 2016 as well as Prnewswire.com‘s news article titled: “Dechra® Pharmaceuticals PLC: Trading Update & Notice of 2016 Annual Results” with publication date: July 12, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>